Two genes identified in our study (ITPKB, CCDC12) demonstrated significant stratification of low and high risk AML patient survival (P = 0.03 CI = 55), with higher significance than RUNX1 status alone (P = 0.08 CI=52). Here, ITPKB is linked to acute myeloid leukemia.